详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
目的探讨胰岛素受体酪氨酸激酶(TK)活性变化在胰岛素抵抗(IR)发生中的作用。
Objective to investigate the change of insulin receptor tyrosine kinase (TK) activity in the pathogenesis of insulin resistance (IR).
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
当第一个逐步变化的跨膜受体酪氨酸激酶通过一个受体被另外一个受体磷酸化而轻易实现临时激活时，我怀疑这种作用方式。
I suspect the way this worked when the first transmembrane receptors tyrosine kinase evolved was simply to make activation contingent on phosphorylation of one receptor by the other.
受体酪氨酸激酶样孤儿受体1（ROR1）是在B-细胞恶性肿瘤和实体瘤亚群上表达的，但不在健康B细胞或正常产后组织中表达。
Receptor tyrosine kinase-like orphan receptor-1 (ROR1) is expressed on sub-populations of B-cell malignancies and solid tumors, but not by healthy B cells or normal postpartum tissues.
属于酪氨酸激酶受体，可以传递表皮生长因子家族的信号。
The family of ErbB tyrosine kinase receptors can transmit signals derived from growth factor of epidermal growth factor family.
目的：研究散发型甲状腺髓样癌酪氨酸激酶受体基因（RET）的突变情况。
Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma.
血管内皮细胞生长因子与其受体结合后通过酪氨酸激酶途径引起细胞的增殖及新生血管形成。
Vascular epithelial growth factor binding with its receptor leads to cell proliferation and new vascular formation by tyrosine kinase pathway.
FLT3L结合到与它同源的酪氨酸激酶的受体FLT3结合激活STAT3和STAT 5 (1,3)。
Binding of FLT3L to its cognate tyrosine kinase receptor, FLT3, activates STAT3 and STAT5 (1, 3).
目的：探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。
Objective: to study Somatic mutation of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR gene) in lung adenocarcinoma patients.
酪氨酸激酶型受体、G蛋白偶联受体和离子通道型受体是细胞表面三类主要受体。
Receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCR) and ion channel receptors are main cell surface receptors.
方法：对原发性高血压伴胰岛素抵抗患者胰岛素受体基因酪氨酸激酶域外显子17、18基因突变进行检测，并对突变的外显子进行核苷酸序列分析。
Methods: Using PCR SSCP, we detected the mutation of INSR tyrosine kinase domain exon 17 and exon 18 in 33 primary hypertension patients and 28 normal persons.
研究证实了源于颗粒细胞的酪氨酸激酶受体配体在卵母细胞生长过程中起重要作用。
It has been demonstrated that granular cell-derived kit ligand (KitL) plays important roles in oocyte growth.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
鉴定了分子量为130000酪氨酸磷酸化的蛋白质为JAK2，一种非受体型酪氨酸激酶。
The tyrosine phosphorylated 130000 protein was identified as JAK2, a non receptor tyrosine kinase.
鉴定了分子量为130000酪氨酸磷酸化的蛋白质为JAK2，一种非受体型酪氨酸激酶。
The tyrosine phosphorylated 130000 protein was identified as JAK2, a non receptor tyrosine kinase.
应用推荐